- Home
- IGMS vs PDSB Comparison
IGMS vs PDSB Comparison
Compare IGMS & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- PDSB
- Stock Information
- Founded
- IGMS 1993
- PDSB 2005
- Country
- IGMS United States
- PDSB United States
- Employees
- IGMS N/A
- PDSB N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- PDSB Biotechnology: Pharmaceutical Preparations
- Sector
- IGMS Health Care
- PDSB Health Care
- Exchange
- IGMS Nasdaq
- PDSB Nasdaq
- Market Cap
- IGMS 82.1M
- PDSB 72.2M
- IPO Year
- IGMS 2019
- PDSB N/A
- Fundamental
- Price
- IGMS $1.26
- PDSB $1.41
- Analyst Decision
- IGMS Hold
- PDSB Strong Buy
- Analyst Count
- IGMS 8
- PDSB 2
- Target Price
- IGMS $6.14
- PDSB $10.00
- AVG Volume (30 Days)
- IGMS 172.4K
- PDSB 738.2K
- Earning Date
- IGMS 05-13-2025
- PDSB 05-14-2025
- Dividend Yield
- IGMS N/A
- PDSB N/A
- EPS Growth
- IGMS N/A
- PDSB N/A
- EPS
- IGMS N/A
- PDSB N/A
- Revenue
- IGMS $2,681,000.00
- PDSB N/A
- Revenue This Year
- IGMS $124.45
- PDSB N/A
- Revenue Next Year
- IGMS $45.07
- PDSB N/A
- P/E Ratio
- IGMS N/A
- PDSB N/A
- Revenue Growth
- IGMS 27.36
- PDSB N/A
- 52 Week Low
- IGMS $0.92
- PDSB $0.85
- 52 Week High
- IGMS $22.50
- PDSB $4.42
- Technical
- Relative Strength Index (RSI)
- IGMS 51.89
- PDSB 53.22
- Support Level
- IGMS $1.13
- PDSB $1.33
- Resistance Level
- IGMS $1.42
- PDSB $1.47
- Average True Range (ATR)
- IGMS 0.09
- PDSB 0.12
- MACD
- IGMS 0.01
- PDSB -0.01
- Stochastic Oscillator
- IGMS 52.94
- PDSB 36.04
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About PDSB PDS Biotechnology Corporation
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.